| Age (yr) . | Sex . | Sex (donor) . | Indication . | Time after TX (mo) . | % XIST+ . | % RPS4Y1+ . |
|---|---|---|---|---|---|---|
| 59 | M | F | IPF | 8.4 | 10.48 | 59.73 |
| 20 | F | M | CF | 20.7 | 70.08 | 0.54 |
| 58 | F | M | COPD | 55.2 | 55.84 | 0.32 |
| 46 | F | M | CF | 112.8 | 72.88 | 0.19 |
| Age (yr) . | Sex . | Sex (donor) . | Indication . | Time after TX (mo) . | % XIST+ . | % RPS4Y1+ . |
|---|---|---|---|---|---|---|
| 59 | M | F | IPF | 8.4 | 10.48 | 59.73 |
| 20 | F | M | CF | 20.7 | 70.08 | 0.54 |
| 58 | F | M | COPD | 55.2 | 55.84 | 0.32 |
| 46 | F | M | CF | 112.8 | 72.88 | 0.19 |
CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; F, female; IPF, idiopathic pulmonary fibrosis; M, male; TX, transplant.